- Global Pharma News & Resources

Esperite N.V. (ESP) : Update to the market on the publication of the Annual Report 2017.

Amsterdam, The Netherlands - 31 August 2018

Esperite NV announced mid-August that the Company had solved the technical issues that caused the delay regarding the publication of the Annual Report 2017. The departments involved made significant progress to finalize the Annual Report 2017.

Esperite continues to strive to publish its Annual Report 2017 and Half year Results 2018 as promptly as practicable.

ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.
To learn more about the ESPERITE Group, or to book an interview with CEO Frédéric Amar:  +31 575 548 998  -  or visit the websites at and .


This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014 (Market Abuse Regulation).

PR delay AR 2017

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Esperite N.V. via GlobeNewswire

Editor Details

Last Updated: 01-Sep-2018